Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 82 of the 85 references it cites were found in a registry or an index; 14 of the 54 sources its claims cite were checked for support.

Tenascin-X, Congenital Adrenal Hyperplasia, and the CAH-X Syndrome

Open access
Miller, Walter L., Merke, Deborah P. · 2018 · Hormone Research in Paediatrics

Abstract

Mutations of the CYP21A2 gene encoding adrenal 21-hydroxylase cause congenital adrenal hyperplasia (CAH). The CYP21A2 gene is partially overlapped by the TNXB gene, which encodes an extracellular matrix protein called Tenascin-X (TNX). Mutations affecting both alleles of TNXB cause a severe, autosomal recessive form of Ehlers-Danlos syndrome (EDS). Rarely, patients with severe, salt-wasting CAH have deletions of CYP21A2 that extend into TNXB, resulting in a “contiguous gene syndrome” consisting of CAH and EDS. Heterozygosity for TNXB mutations causing haploinsufficiency of TNX may be associated with the mild “hypermobility form” of EDS, which principally affects small and large joints. Studies of patients with salt-wasting CAH found that up to 10% had clinical features of EDS, associated joint hypermobility, haploinsufficiency of TNX and heterozygosity for TNXB mutations, now called “CAH-X.” These patients have joint hypermobility and a spectrum of other comorbidities associated with their connective tissue disorder, including chronic arthralgia, joint subluxations, hernias, and cardiac defects. Other disorders are beginning to be associated with TNX deficiency, including familial vesicoureteral reflux and neurologic disorders. Further work is needed to delineate the full spectrum of TNX-deficient disorders, with and without associated CAH.

Overview

CoChat Summary

TL;DR

CAH-X is a contiguous gene syndrome in which CYP21A2 deletions extend into TNXB, producing congenital adrenal hyperplasia plus Tenascin-X–related Ehlers-Danlos features. This review summarizes the genetics, TNXA/TNXB chimeras, and clinical spectrum, estimating that about 10% of patients with CAH due to 21-hydroxylase deficiency are affected by CAH-X.

Key findings

  • Heterozygosity for a TNXB deletion was present in 7% of 193 consecutive unrelated CAH patients; these patients were more likely to have joint hypermobility, chronic joint pain, multiple joint dislocations, and structural cardiac valve abnormality.
  • Approximately 10% of patients with CAH due to 21-hydroxylase deficiency are estimated to be affected by CAH-X; overall CAH-X patients have generalized joint hypermobility, subluxations, chronic arthralgia, and about 25% have cardiac abnormalities.
  • To date, 24 patients (19 families) with monoallelic CAH-X and 5 patients (5 families) with biallelic CAH-X have been described. CAH-X CH-2 causes a more severe phenotype than CAH-X CH-1, with greater skin and joint involvement; 40% of CAH-X CH-2 patients had skin laxity, while patients heterozygous for CAH-X CH-1 had normal skin.
  • Among 20 obligate heterozygotes for a severely defective TNXB allele, 9 of 14 females but no males had hypermobility EDS.

Methods

  • Narrative review of the genetics, molecular biology, and clinical phenotype of CAH-X, Tenascin-X deficiency, and related disorders.
  • Synthesizes prior studies, including an NIH observational study of 193 consecutive unrelated CAH patients, a study of 151 EDS patients of unknown etiology, and case series of monoallelic and biallelic CAH-X.
  • Main analysis is literature synthesis linking TNXA/TNXB chimeric recombination, TNX protein effects, and clinical features; no new primary data or meta-analysis are reported.

Limitations

  • The paper states that further work is needed to delineate the full spectrum of TNX-deficient disorders, with and without associated CAH.
  • The paper states that variations within TNXA and TNXB have not been investigated in detail, that computational analysis of CH-2/CH-3 protein effects is imperfect and needs experimental verification, and that the CAH phenotype associated with heterozygosity for CAH-X CH-3 is unknown because CH-3 has only been described in biallelic CAH-X.
  • Evident from the text: this is a narrative review without a systematic search strategy, and rare-genotype conclusions rest on small numbers; the authors also note that hormonal factors characteristic of CAH, including chronic glucocorticoid treatment, may influence phenotype.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1159/000481911

Cites

82 of 82 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

4 Valid · 4 Not valid · 25 Not checked · 9 Own results and interpretations

19 more claims

Create a free account to see all 42 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 14
  • Probably not a substantial claim. 5

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

5 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 85 references

Cited by

See all 62

Metadata

Authors
Miller, W. L., & Merke, D. P.
Affiliations
  • University of California, San Francisco (US)
  • National Institutes of Health (US)
Venue
Hormone Research in Paediatrics
Publisher
S. Karger AG
Published
2018
Volume
89
Issue
5
Pages
352-361
ISSN
  • 1663-2818 (ISSN-L)
  • 1663-2826
OpenAlex
W2802388328
Cited by
61
References
85
Citations by year
2026: 2 · 2025: 6 · 2024: 7 · 2023: 7 · 2022: 11 · 2021: 13 · 2020: 8 · 2019: 4 · 2018: 2
FWCI
0.93
Type
journal article
Language
en
Open access
Licence
Locations
  • Hormone Research in Paediatrics (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
National Institutes of Health (Z99CL999999)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Connective tissue disorders research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
Keywords
tenascin-X, congenital adrenal hyperplasia, CYP21A2, TNXB, salt-wasting CAH, Ehlers-Danlos syndrome, contiguous gene syndrome, haploinsufficiency, joint hypermobility, extracellular matrix, connective tissue diseases, joint pain, vesicoureteral reflux
MeSH terms
Adrenal Hyperplasia, Congenital, Ehlers-Danlos Syndrome, Humans, Mutation, Steroid 21-Hydroxylase, Syndrome, Tenascin, Haploinsufficiency

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tenascin-X, Congenital Adrenal Hyperplasia, and the CAH-X Syndrome. https://app.cochat.ai/papers/10.1159/000481911
The paper
Miller, W. L., & Merke, D. P. (2018). Tenascin-X, Congenital Adrenal Hyperplasia, and the CAH-X Syndrome. Hormone Research in Paediatrics. https://doi.org/10.1159/000481911

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.